BriaCell Therapeutics Corp.
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$26.3M
- Total assets
- $21.6M
- Market cap
- $26.8M
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $27.2M
- Operating income
- -$27.2M
- Net income
- -$26.6M
- EPS (basic)
- $-62.19
- EPS (diluted)
- $-62.19
Balance sheet
- Total assets
- $21.6M
- Current assets
- $19.9M
- Total liabilities
- $4.3M
- Current liabilities
- $4.0M
- Shareholders’ equity
- $17.3M
Cash flow
- Operating cash flow
- -$28.2M
- Investing cash flow
- -$7.6M
- Financing cash flow
- $45.4M
- Net cash flow
- $9.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $26.8M
- EPS (diluted)
- $-62.19
- Shares outstanding
- 8.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 5, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $26.3M.
- Trading 92% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BriaCell Therapeutics Corp..
Write a review
News about BriaCell Therapeutics Corp.
News & sentiment via Polygon.io
